Mazur Leonard L 4
4 · Citius Pharmaceuticals, Inc. · Filed Sep 27, 2024
Insider Transaction Report
Form 4
Mazur Leonard L
DirectorChief Executive Officer
Transactions
- Award
Warrant to Purchase Common Stock
2024-09-25+2,234,700→ 2,234,700 totalExercise: $0.77Exp: 2025-09-27→ Common Stock (2,234,700 underlying) - Disposition to Issuer
Warrant to Purchase Common Stock
2024-08-14−3,137,255→ 0 totalExercise: $1.15Exp: 2024-08-14→ Common Stock (3,137,255 underlying) - Award
Warrant to Purchase Common Stock
2024-08-14+3,137,255→ 3,137,255 totalExercise: $1.15Exp: 2025-08-14→ Common Stock (3,137,255 underlying) - Disposition to Issuer
Warrant to Purchase Common Stock
2024-09-25−2,234,700→ 0 totalExercise: $0.77Exp: 2024-09-27→ Common Stock (2,234,700 underlying)
Holdings
- 40,000
Stock Option (Right to Purchase Common Stock)
Exercise: $3.45Exp: 2027-09-13→ Common Stock (40,000 underlying) - 1,165,048
Warrant to Purchase Common Stock
Exercise: $1.42Exp: 2025-04-05→ Common Stock (1,165,048 underlying) - 10,255,343
Common Stock
- 550,000
Stock Option (Right to Purchase Common Stock)
Exercise: $1.25Exp: 2032-10-04→ Common Stock (550,000 underlying) - 650,000
Stock Option (Right to Purchase Common Stock)
Exercise: $2.04Exp: 2031-10-11→ Common Stock (650,000 underlying) - 550,000
Stock Option (Right to Purchase Common Stock)
Exercise: $0.70Exp: 2033-10-10→ Common Stock (550,000 underlying) - 200,000
Stock Option (Right to Purchase Common Stock)
Exercise: $1.01Exp: 2030-10-06→ Common Stock (200,000 underlying) - 300,000
Stock Option (Right to Purchase Common Stock)
Exercise: $2.00Exp: 2031-07-22→ Common Stock (300,000 underlying) - 175,000
Stock Option (Right to Purchase Common Stock)
Exercise: $0.67Exp: 2029-10-08→ Common Stock (175,000 underlying) - 150,000
Stock Option (Right to Purchase Common Stock)
Exercise: $1.62Exp: 2028-09-04→ Common Stock (150,000 underlying)
Footnotes (7)
- [F1]The two reported transactions involved an amendment of an outstanding warrant to extend the termination date from August 14, 2024 to August 14, 2025, which resulted in the cancellation of the "old" warrant and the grant of a replacement warrant. The warrant was originally issued on August 13, 2018 and was exercisable immediately.
- [F2]The two reported transactions involved an amendment of an outstanding warrant to extend the termination date from September 27, 2024 to September 27, 2025, which resulted in the cancellation of the "old" warrant and the grant of a replacement warrant. The warrant was originally issued on September 27, 2019 and was exercisable immediately.
- [F3]The warrant is fully vested and exercisable immediately.
- [F4]The options were granted on October 10, 2023. The options will vest 1/3 on each of the one-year, two-year and three-year anniversary of the Vesting Commencement Date, provided that the Optionee provides Continuous Service to the Company as of each such vesting date.
- [F5]The options were granted on October 4, 2022. The options will vest 1/3 on each of the one-year, two-year and three-year anniversary of the Vesting Commencement Date, provided that the Optionee provides Continuous Service to the Company as of each such vesting date.
- [F6]The options were granted on October 11, 2021. The options will vest 1/3 on each of the one-year, two-year and three-year anniversary of the Vesting Commencement Date, provided that the Optionee provides Continuous Service to the Company as of each such vesting date.
- [F7]The options are vested in full and exercisable immediately.